[Clinical pharmacokinetics of kanamycin in endolymphatic therapy of peritonitis].
The pharmacokinetics of kanamycin in patients with peritonitis was studied after its intramuscular, endolymphatic and lymphotropic administration. Endolymphatic administration of kanamycin provided an increase in its activity in the inflamed tissues of the peritoneum and omentum and markedly prolonged its halflife as compared to those after the routine intramuscular administration of the drug. Lymphotropic administration of kanamycin failed to provide the same effect. Endolymphatic therapy of the patients during the postoperative period provided a decrease in the lethality, development of complications and the terms of the treatment in the hospital. The therapeutic effect of the endolymphatic administration of kanamycin to the patients with peritonitis proved to be high. The more efficient antibiotic therapy of the cases was likely due to favourable shifts in the pharmacokinetics of kanamycin after its endolymphatic administration.
Lokhvitskiĭ
S V
SV
Klepatskiĭ
V G
VG
Guliaev
A E
AE
Gaĭdukova
G P
GP
Kivman
G Ia
GIa
D000293:Adolescent; D000328:Adult; D000368:Aged; D001202:Ascitic Fluid / Q000378:metabolism; D006207:Half-Life; D006801:Humans; D007272:Injections, Intralymphatic; D007273:Injections, Intramuscular; D007612:Kanamycin / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D008875:Middle Aged; D009852:Omentum; D010537:Peritoneum / Q000378:metabolism; D010538:Peritonitis / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism
D007612:Kanamycin
Klinicheskaia farmakokinetika kanamitsina pri éndolimfaticheskoĭ terapii peritonita.